Immunai Stock
HealthTechLooking to sell Immunai stock or options?
Immunai is a bioinformatics platform designed to enhance our understanding of complex diseases and develop targeted therapies more effectively. The company's platform leverages artificial intelligence to analyze large-scale biological datasets and predict treatment outcomes, enabling healthcare researchers to optimize drug discovery and development processes.
Meron Capital, Endless Frontier Labs, 8VC, Alexandria Venture Investments, Gefen Capital, Perot Jain, Dexcel Pharma, Piedmont Capital Investments, Talos Ventures, Duquesne Family Office, iAngels, TLV Partners, Schusterman Family Investments, ICON (Palo Alto), R-Squared Ventures, Koch Disruptive Technologies, Gad Allon, Piedmont, MIT Startup Exchange, Viola Ventures, Catalio Capital Management.